Journal article
Phenotypic, Functional, and Gene Expression Profiling of Peripheral CD45RA and CD45RO CD4 CD25 CD127low Treg Cells in Patients with Chronic Rheumatoid Arthritis
GJ Walter, V Fleskens, KS Frederiksen, M Rajasekhar, B Menon, JG Gerwien, HG Evans, LS Taams
Arthritis and Rheumatology | WILEY | Published : 2016
DOI: 10.1002/art.39408
Abstract
Objective Conflicting evidence exists regarding the suppressive capacity of Treg cells in the peripheral blood (PB) of patients with rheumatoid arthritis (RA). The aim of this study was to determine whether Treg cells are intrinsically defective in RA. Methods Using a range of assays on PB samples from patients with chronic RA and healthy controls, CD3+CD4+CD25+CD127low Treg cells from the CD45RO+ or CD45RA+ T cell compartments were analyzed for phenotype, cytokine expression (ex vivo and after in vitro stimulation), suppression of Teff cell proliferation and cytokine production, suppression of monocyte-derived cytokine/chemokine production, and gene expression profiles. Results No differenc..
View full abstractGrants
Awarded by European Commission
Funding Acknowledgements
Supported by Arthritis Research UK (grant 19307), the Innovative Medicines Initiative (BTCure grant 115142-2), and the Department of Health (NIHR Biomedical Research Centre award to Guy's and St. Thomas' NHS Foundation Trust in partnership with King's College London and King's College Hospital NHS Foundation Trust). Dr. Frederiksen owns stock or stock options in Novo Nordisk. Dr. Taams has received speaking fees from UCB and GlaxoSmithKline (less than $10,000 each) and research support from Novo Nordisk, UCB, and GlaxoSmithKline.